Method of treating organophosphate intoxication

A method, comprising:

• a) providing;
• i) a subject exhibiting a cholinergic crisis subsequent to an organophosphate compound exposure;
• and
• ii) a pharmaceutical composition comprising a neurosteroid and an organophosphate antidote selected from the group consisting of atropine and pralidoxime;
• and
• b) administering said pharmaceutical composition to said subject under conditions such that said cholinergic crisis is reduced.

A method, comprising:

• a) providing;
• i) a subject exhibiting at least one symptom of a non-cholinergic crisis subsequent to an organophosphate compound exposure;
• and
• ii) a composition comprising a neurosteroid and a pharmaceutical carrier;
• and
• b) administering said composition to said subject under conditions such that said at least one symptom of said non-cholinergic crisis is reduced.

A method, comprising:

• a) providing;
• i) a subject exhibiting a cholinergic crisis subsequent to an organophosphate compound exposure;
• and
• ii) a pharmaceutical composition comprising a neurosteroid and a benzodiazepine adjunct selected from the group consisting of midazolam, diazepam and lorazepam;
• and
• b) administering said pharmaceutical composition to said subject under conditions such that said cholinergic crisis is reduced.

A method, comprising:

• a) providing;
• i) a subject exhibiting at least one late-onset or long-term neuropsychiatric symptom of a cholinergic or non-cholinergic crisis subsequent to an organophosphate compound exposure;
• and
• ii) a composition comprising a neurosteroid and a pharmaceutical carrier;
• and
• b) administering said composition to said subject under conditions such that said at least one late-onset or long-term neuropsychiatric symptom of said cholinergic or non-cholinergic crisis is reduced.